Rockwell Medical Files Q3 2024 10-Q

TL;DR

Rockwell Medical's Q3 2024 10-Q is in: check financials for latest performance.

AI Summary

Rockwell Medical, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial performance and position, including its balance sheet, income statement, and cash flow statement for the third quarter and the year-to-date period. Specific financial figures and operational details are presented within the report.

Why It Matters

This filing provides investors and analysts with the latest financial data for Rockwell Medical, Inc., crucial for understanding the company's performance and making informed investment decisions.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains detailed financial information that can reveal both positive and negative trends, requiring careful analysis to assess risk.

Key Numbers

• 20240930 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial data is reported.)
• 20241112 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• ROCKWELL MEDICAL, INC. (company) — Filer of the 10-Q
• 20240930 (date) — End of the reporting period
• 20241112 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — ch registered: Common Stock, par value $0.0001 RMTI Nasdaq Capital Market The number

Filing Documents

• rmti-20240930.htm (10-Q) — 1149KB
• rmti-20240930x10qex311.htm (EX-31.1) — 9KB
• rmti-20240930x10qex321.htm (EX-32.1) — 5KB
• 0001628280-24-046839.txt ( ) — 7686KB
• rmti-20240930.xsd (EX-101.SCH) — 60KB
• rmti-20240930_cal.xml (EX-101.CAL) — 93KB
• rmti-20240930_def.xml (EX-101.DEF) — 325KB
• rmti-20240930_lab.xml (EX-101.LAB) — 678KB
• rmti-20240930_pre.xml (EX-101.PRE) — 506KB
• rmti-20240930_htm.xml (XML) — 1115KB

— Financial Information (unaudited)

Part I — Financial Information (unaudited)

- Unaudited Financial Statements

Item 1 - Unaudited Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023 5 Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2024 and 2023 6 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Nine Months Ended September 30, 2024 and 2023 7 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 8 Notes to Condensed Consolidated Financial Statements 9

- Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations 16

- Quantitative and Qualitative Disclosures about Market Risk

Item 3 - Quantitative and Qualitative Disclosures about Market Risk 18

- Controls and Procedures

Item 4 - Controls and Procedures 18

— Other Information

Part II — Other Information

- Legal Proceedings

Item 1 - Legal Proceedings 18

- Risk Factors

Item 1A - Risk Factors 19

- Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 19

- Defaults Upon Senior Securities

Item 3 - Defaults Upon Senior Securities 19

- Mine Safety Disclosures

Item 4 - Mine Safety Disclosures 19

- Other Information

Item 5 - Other Information 19

- Exhibits

Item 6 - Exhibits 19

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ROCKWELL MEDICAL, INC. AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and par value amounts) September 30, 2024 December 31, 2023 ASSETS Cash and Cash Equivalents $ 12,338 $ 8,983 Investments Available-for-Sale 5,934 1,952 Accounts Receivable, net 8,886 10,901 Inventory, net 5,888 5,871 Prepaid and Other Current Assets 1,171 1,063 Total Current Assets 34,217 28,770 Property and Equipment, net 5,795 6,402 Inventory, Non-Current 178 178 Right of Use Assets - Operating, net 3,598 2,713 Right of Use Assets - Financing, net 1,482 1,903 Intangible Assets, net 10,345 10,759 Goodwill 921 921 Other Non-Current Assets 548 527 Total Assets $ 57,084 $ 52,173 LIABILITIES AND STOCKHOLDERS' EQUITY Accounts Payable $ 2,607 $ 4,516 Accrued Liabilities 6,290 7,149 Deferred Consideration - Current 2,274 2,500 Lease Liabilities - Operating - Current 1,554 1,381 Lease Liabilities - Financing - Current 587 558 Deferred License Revenue - Current 46 46 Insurance Financing Note Payable 469 244 Customer Deposits 351 243 Total Current Liabilities 14,178 16,637 Lease Liabilities - Operating - Long-Term 2,098 1,433 Lease Liabilities - Financing - Long-Term 1,085 1,530 Term Loan - Long-Term, net of issuance costs 8,383 8,293 Deferred License Revenue - Long-Term 441 475 Deferred Consideration - Long-Term 1,750 2,500 Long Term Liability - Other 14 14 Total Liabilities 27,949 30,882 3 September 30, 2024 December 31, 2023 Stockholders' Equity: Preferred Stock, $ 0.0001 par value, 2,000,000 shares authorized; 15,000 shares issued and outstanding at September 30, 2024 and December 31, 2023 — — Common Stock, $ 0.0001 par value; 170,000,000 shares authorized; 32,318,806 and 29,130,607 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 3 3 Additional Paid-in Capital 426,046 418,487 Accumulated Deficit ( 396,922 ) ( 397,198 ) Accumulated Othe

View Full Filing

View this 10-Q filing on SEC EDGAR